Welcome to our dedicated page for Larimar Therapeutics SEC filings (Ticker: LRMR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Larimar Therapeutics’ dense clinical-stage disclosures can feel like sequencing DNA. Trial endpoints for CTI-1601, orphan-drug designations, and intricate R&D spending hide across multiple forms. If you’ve asked, “How do I find Larimar Therapeutics insider trading Form 4 transactions?” or “Where’s the Larimar Therapeutics annual report 10-K simplified?” you already know the challenge.
Stock Titan solves it. Our AI-powered summaries translate biotech jargon into plain language, so understanding Larimar Therapeutics SEC documents with AI takes minutes, not days. Receive real-time alerts the moment a Larimar Therapeutics Form 4 insider transactions real-time filing posts, skim concise breakdowns of every Larimar Therapeutics quarterly earnings report 10-Q filing, and see key takeaways from 8-K material events explained. Whether you’re tracking Larimar Therapeutics executive stock transactions Form 4, scanning a proxy statement executive compensation table, or seeking a Larimar Therapeutics earnings report filing analysis, our platform keeps each disclosure neatly indexed and continuously updated from EDGAR.
Investors use these insights to monitor pipeline milestones, gauge cash runway, and spot insider confidence before pivotal FDA readouts. Explore sections that pinpoint which 10-K pages discuss manufacturing scale-up, or view side-by-side comparisons of Form 4 buys versus CTI-1601 trial timelines. From Larimar Therapeutics 8-K material events explained to a Larimar Therapeutics annual report 10-K simplified, every document is decoded so you can make informed decisions backed by data, not guesswork.
Larimar Therapeutics (LRMR) is advancing nomlabofusp through clinical development with multiple recent regulatory and clinical milestones. The company increased open-label dosing to 50 mg daily and has active participants receiving that dose. In March 2025 the Safety Monitoring Team deemed anaphylaxis a likely adverse drug reaction and the protocol was amended to add antihistamine premedication for the first month. Adolescent PK run-in dosing (ages 12–17) completed dosing of 14 participants in March 2025 and some adolescents are transitioning into the open-label study.
Regulatory interactions include FDA acceptance of a lyophilized formulation for clinical use and FDA feedback under the START pilot that it is open to considering skin FXN concentration as a reasonably likely surrogate endpoint, subject to review in a future marketing application. FDA recommended safety database targets for an accelerated BLA: at least 30 participants with six months continuous exposure and a subset of at least 10 with one year. Larimar plans a BLA submission in Q2 2026. A July 2025 publication reported supporting nonclinical data. The company raised net proceeds of approximately $65.1 million in July 2025, which management expects to fund operations into Q4 2026.
Janus Henderson Group plc filed Amendment No. 5 to a Schedule 13G reporting its position in Larimar Therapeutics, Inc. (CUSIP 517125100). The filing states that Janus Henderson and certain indirect subsidiaries beneficially own 0 shares of Larimar common stock, representing 0.0% of the class. The report lists Janus Henderson as Type IA, HC with a principal address at 201 Bishopsgate, EC2M 3AE, United Kingdom, and shows 0 sole and shared voting and dispositive powers. The filing names JHIUS, JHIUKL and JHIAIFML as indirect subsidiaries providing investment advice to Managed Portfolios and includes a power of attorney dated December 9, 2022. The statement is signed by Kristin Mariani on 08/14/2025.
Larimar Therapeutics, Inc. announced its financial results and operational highlights for the second quarter ended June 30, 2025, via a press release furnished on August 14, 2025. The Current Report does not include the numerical results in-line but references that the press release is provided as Exhibit 99.1.
The company also posted an updated corporate slide presentation on its website, furnished as Exhibit 99.2, which company representatives will use in investor and analyst meetings. The filing states the furnished materials are intended to be "furnished" and not "filed" under the Exchange Act.
Form 4 filed 8 Aug 2025 shows that Deerfield-affiliated funds led by managing partner James E. Flynn increased their ownership in Larimar Therapeutics (LRMR).
- Date of trade: 31 Jul 2025
- Type: Open-market purchases (Code “P”)
- Shares bought: 9,375,000 common shares in aggregate:
- Deerfield Private Design Fund III: 3,387,529 sh @ $3.20
- Deerfield Private Design Fund IV: 3,387,539 sh @ $3.20
- Deerfield Healthcare Innovations Fund: 2,599,932 sh @ $3.20
- Cash outlay: ≈ $30.0 million
- Post-trade holdings (indirect): Fund III 9.54 m, Fund IV 9.54 m, HIF 7.32 m, Deerfield Partners 4.21 m shares
- Flynn, Deerfield Mgmt entities and the funds remain directors by deputization and >10 % beneficial owners.
The filing consolidates positions across multiple Deerfield vehicles; each filer disclaims beneficial ownership beyond its economic interest. No derivative transactions were reported.
Larimar Therapeutics, Inc. (Nasdaq: LRMR) filed a Form 8-K to notify investors that an updated corporate slide deck dated June 23, 2025 has been posted to the company’s website and furnished as Exhibit 99.1. The presentation will be used in meetings with investors, analysts and other stakeholders. No new financial results, transactions, or strategic changes were disclosed in the filing. Apart from the presentation and customary Exhibit 104 (Inline XBRL cover page data), the 8-K contains no other material information. The filing is therefore primarily an investor-relations housekeeping action, aimed at ensuring Regulation FD compliance by making the slides publicly available to all market participants.
Larimar Therapeutics (Nasdaq: LRMR) filed a Form 8-K to disclose a regulatory update issued on June 23, 2025. The company released a press release (Exhibit 99.1) stating that the U.S. Food and Drug Administration provided safety-database recommendations and requested additional adult and pediatric data for patients with Friedreich’s Ataxia. To incorporate these data, Larimar has established a “refined timeline” for its forthcoming Biologics License Application (BLA).
The filing notes that management will host a conference call the same day and use a supporting slide deck (Exhibit 99.2) to discuss the regulatory feedback and the updated submission schedule. No financial statements were included; the 8-K is limited to Item 8.01 (Other Events) and Item 9.01 (Exhibits).
For investors, the disclosure is material because FDA feedback can directly influence the timing of commercialization for the company’s lead program targeting Friedreich’s Ataxia. While the agency’s recommendations clarify the data package required, the need to gather and integrate additional safety data could shift the expected BLA submission date, affecting near-term milestones, cash runway assumptions, and valuation timelines.
FAQ
What is the current stock price of Larimar Therapeutics (LRMR)?
What is the market cap of Larimar Therapeutics (LRMR)?
